Cargando…
Higher Urine bis(Monoacylglycerol)Phosphate Levels in LRRK2 G2019S Mutation Carriers: Implications for Therapeutic Development
BACKGROUND: LRRK2 mutations are a common cause of dominantly inherited PD. Previous studies showed decreases in urine levels of didocohexaenoyl (22:6) bis(monoacylglycerol)phosphate in LRRK2‐knockout mice and in non‐human primates treated with LRRK2 kinase inhibitors. We hypothesized that urine leve...
Autores principales: | Alcalay, Roy N., Hsieh, Frank, Tengstrand, Elizabeth, Padmanabhan, Shalini, Baptista, Marco, Kehoe, Caitlin, Narayan, Sushma, Boehme, Amelia K., Merchant, Kalpana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6981003/ https://www.ncbi.nlm.nih.gov/pubmed/31505072 http://dx.doi.org/10.1002/mds.27818 |
Ejemplares similares
-
Elevated urine BMP phospholipids in LRRK2 and VPS35 mutation carriers with and without Parkinson’s disease
por: Gomes, Sara, et al.
Publicado: (2023) -
An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson’s Disease and G2019S LRRK2 Cohorts
por: Padmanabhan, Shalini, et al.
Publicado: (2020) -
LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts
por: Merchant, Kalpana M., et al.
Publicado: (2023) -
Plasma Glucosylsphingosine in
GBA1
Mutation Carriers with and without Parkinson's Disease
por: Surface, Matthew, et al.
Publicado: (2021) -
Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort
por: Simuni, Tanya, et al.
Publicado: (2022)